Flaccid Blisters and a Contraindication to High-Dose Steroids
A 58-year-old woman presents with a 3-month history of painful oral erosions and flaccid blisters on the trunk and scalp. Nikolsky sign is positive at the edge of a blister. She has type 2 diabetes (HbA1c 9.4%), hypertension, and chronic kidney disease with an eGFR of 36 mL/min/1.73 m². For the past 2 weeks she has applied clobetasol 0.05% ointment to two truncal lesions. You plan a punch biopsy and direct immunofluorescence (DIF). Serology returns positive anti-desmoglein 3 and negative anti-desmoglein 1 and anti-BP180. DIF shows intercellular IgG and C3 in the epidermis. She has no history of malignancy, tuberculosis, or hepatitis B, and her chest radiograph is normal. She asks whether she can avoid steroids because her diabetes is poorly controlled. Her medications include metformin, insulin glargine, and amlodipine.
1. Explain how the biopsy site and prior topical clobetasol influence the histologic and DIF interpretation, and justify the diagnosis.
Read the worked answer
Biopsy site
The correct sample is perilesional skin, not the blister roof or an eroded base. In pemphigus vulgaris, acantholysis splits the epidermis above the basal layer; a blister-roof specimen may show only necrotic epidermis, and an eroded base may show nonspecific inflammation. Perilesional skin preserves the intercellular IgG and C3 binding that defines the disease.
Effect of topical clobetasol
Two weeks of a superpotent topical steroid can reduce inflammation and antigen expression at the treated site. If the biopsy is taken from treated skin, DIF may be falsely negative or weakly positive. The practical response is to biopsy an untreated or distant perilesional site; if only treated skin is available and DIF is negative, repeat after a short steroid-free interval rather than accepting a false-negative result.
Interpretation
The combination of suprabasal acantholysis, intercellular epidermal IgG/C3, and anti-desmoglein 3 positivity is diagnostic of mucosal-dominant pemphigus vulgaris. Negative anti-desmoglein 1 explains the prominent oral disease with limited cutaneous blistering. Anti-BP180 negativity argues against bullous pemphigoid.
2. Given her diabetes and renal impairment, outline an initial treatment plan with doses and monitoring, and justify why standard high-dose prednisolone alone is a poor choice.
Read the worked answer
Why not standard high-dose steroids alone
High-dose prednisolone (1 mg/kg/day) would worsen her HbA1c of 9.4% and increase infection, osteoporosis, and cardiovascular risk. Her eGFR of 36 mL/min/1.73 m² also narrows the safe use of some steroid-sparing drugs. Rituximab is first-line for moderate-to-severe pemphigus and has a better long-term steroid-sparing profile.
Initial plan
- Rituximab: 1,000 mg IV on days 1 and 15 (or 375 mg/m² weekly for 4 weeks). Before infusion, check hepatitis B serology, TB screening, pregnancy test, and baseline IgG; give appropriate prophylaxis if indicated.
- Prednisolone: start at 0.5 mg/kg/day, not 1 mg/kg/day, and taper over weeks once control is achieved. Add bone protection, gastric protection if indicated, and glucose monitoring.
- Topical therapy: adjunctive topical corticosteroid to limited lesions and oral antiseptic rinses; treat oral candidiasis if it develops.
- Monitoring: blood glucose, blood pressure, renal function, CBC, IgG, and infection surveillance. Pneumocystis prophylaxis if the steroid dose or comorbidity warrants it.
Justification
This approach targets the autoantibody-producing B cells while minimizing steroid exposure in a patient with poorly controlled diabetes and renal impairment.
3. At 6 months she has no new lesions and is on prednisolone 5 mg/day. What defines remission, how should treatment be tapered, and what monitoring is needed?
Read the worked answer
Remission
Clinical remission means no new lesions, healing of existing erosions, and no need for new immunosuppression. Anti-desmoglein 3 titers can support follow-up but should not be used alone to make treatment decisions because titers do not always track disease activity.
Taper
If she has been stable for at least 2–3 months, taper prednisolone slowly, for example by 1–2.5 mg every 2–4 weeks, with a goal of stopping or reaching the lowest effective dose. Rituximab is not given routinely as maintenance; consider repeat dosing for relapse or persistent high-risk disease. Do not stop all therapy abruptly after prolonged steroids; adrenal insufficiency is a risk.
Monitoring
Check blood glucose, blood pressure, CBC, renal function, and IgG. Watch for infections, including late-onset neutropenia after rituximab. Review oral and cutaneous disease at each visit. If relapse occurs, re-evaluate for infection and malignancy, check anti-desmoglein titers, and consider repeat rituximab or a steroid-sparing agent rather than simply escalating steroids indefinitely.